Contact lens manufacturing combines high-volume production, delicate ophthalmic products and increasingly sophisticated packaging concepts.
As manufacturers introduce ultra-thin blister formats, easy-peel packaging designs and fully automated production environments, terminal sterilization must ensure both sterility and packaging integrity throughout the entire process.

Hemodialysis blood tubing sets form the extracorporeal connection between the patient and the dialysis system. During treatment, the patient’s entire circulating blood volume passes through a fluid path formed by flexible tubing, chambers, connectors and branches. Any failure in sterility, material compatibility, mechanical integrity or residual control can therefore affect clinical safety.

EtO has historically served these complex devices because of its penetration capability. Transitioning away from it is not a simple change of sterilant.

Drug-device combination products can bring together a thermosensitive drug, a complex delivery system and a protective package within a single sterilization challenge. For blistered prefilled syringes, the process must reach external surfaces, recessed areas and partially enclosed geometries without exposing the filled product to damaging temperatures. Sterilant penetration through the Tyvek® layer must therefore be demonstrated, together with microbial effectiveness inside the blister and around critical syringe components.

IV bags are commonly manufactured in large quantities for the delivery of infusion solutions, electrolytes, nutrients and pharmaceutical formulations. Once filled and sealed, the complete product-container system must reach the required sterility assurance without compromising the formulation, the flexible bag, its seals or its ports.

For high-volume lines, the challenge extends to the economics and continuity of the complete production flow. Process time, bags per batch, loading and unloading, utility demand, water and wastewater, drying and downstream readiness all influence line output and cost per processed bag.

Insulin production increasingly relies on high-throughput syringes and cartridge filling lines, with cartridges serving reusable and disposable delivery pens. At these output levels, filling capacity alone does not determine production performance.

Closures and reusable filling-line parts must be washed, sterilized, handled and delivered to the filling area at the required pace and under controlled aseptic conditions. If these upstream activities are managed as separate, disconnected operations, they can become a bottleneck while increasing equipment, transfers, manual handling and operating costs.

Vaccine manufacturing places exceptional demands on fill-finish operations, where product sterility depends on the controlled preparation and transfer of every component entering the aseptic filling area.

Sterile vials, stoppers and product-contact machine parts must be available in step with the filling line and introduced without contamination or particle exposure. Multiple preparation systems, intermediate containers and manual transfers increase process complexity, footprint and critical interfaces. Dependence on ready-to-use components can also limit sourcing and campaign flexibility.

Albumin is a heat-sensitive biological product. Once prepared, purified, formulated and stabilized, it is sterile-filtered and aseptically filled into final glass vials or bottles. Because it is not subjected to conventional terminal sterilization at 121°C, the filled and sealed containers undergo validated pasteurization at 60°C for at least 10 hours to support viral inactivation while preserving protein stability and product quality.

Albumin pasteurization is traditionally performed in water-bath systems. Although effective for heat transfer, this established approach requires very large quantities of process water, increasing utility consumption, wastewater generation and operating costs across a long and production-critical treatment

High-potent sterile manufacturing is one of the fastest-growing pharmaceutical sectors, driven by oncology biologics, antibody-drug conjugates (ADCs), peptides and other highly active compounds. While aseptic filling remains essential, manufacturers must simultaneously protect product sterility, operators and the surrounding environment. As occupational exposure limits decrease to the ng/m³ range, every reusable machine component leaving the filling isolator becomes a potential contamination source.

Artificial valves combine long-term implant performance with exceptional material and geometrical complexity. Biological tissues or collagen-based components may coexist with implantable textiles, polymeric films, metallic structures and surface treatments. The sterilization process must reach external surfaces, internal cavities, layered structures and interfaces between dissimilar materials without altering mechanical response, dimensional stability, biocompatibility or haemodynamic function.

Packaged surgical sutures combine variables that respond differently to sterilization: absorbable or non-absorbable polymers, braided or monofilament structures, functional coatings and multilayer barrier systems. The combinations to be treated may span Polyglactin 910, Polydioxanone, Polyester, Polyamide, Polypropylene and Polyethylene, together with aluminium pouches, paper–plastic laminates, Tyvek® sterile-barrier systems and more complex polymeric assemblies. Sterilization must therefore do more than achieve microbial inactivation.

RTU manufacturing carries more value - and more responsibility.

Ready-to-use cartridge manufacturers are taking on a critical role in biopharmaceutical supply chains. By supplying cartridges already washed, depyrogenated, siliconized, assembled, packaged and sterile, they enable pharma companies to outsource container preparation and the associated validation burden.

Ready-to-fill vial manufacturers supply pharmaceutical companies with primary containers that are already washed, depyrogenated, packaged and sterile, transferring container preparation and part of its qualification burden upstream. Growing demand for injectable biologics is increasing production volumes while making conventional sterilization routes more difficult to sustain. Steam may exceed the thermal limits of some packaging materials, while EtO introduces toxic-residue concerns and extended degassing times.

Aseptic manufacturing depends on preserving the required state of every material until its point of use. Yet reusable parts, pre-sterilized components, bulk closures, tools and auxiliary materials enter the process from different conditions, through different routes and with different vulnerabilities.

Treatment alone does not secure the flow: unloading, transport, storage, manipulation and connection create critical interfaces where control can be lost. As manufacturing architectures become more closed, integrated and automated, aseptic transfer becomes a system-level responsibility.